Top image

Kate White & team: The financial impact of cancer treatment on Australian patients and families

RESEARCH TYPE
T2
PROGRAM
Flagship 2 Pilot and Seed
TAGS
    Psychosocial
    Cancer costs
STATUS
Complete

It is recognised that individuals and their families experience financial costs associated with the diagnosis of cancer and subsequent treatment.  Little attention has been paid to identifying individuals who may be at risk of experiencing financial hardship earlier in treatment planning stage, and the extent to which this needs to be considered by the treating team.  Similarly, it is not known how financial concerns influence individuals' treatment choices. As individual patients increasingly seek access to treatment through self-funding and public fundraising campaigns, approaches that enable cancer health professionals to determine financial concerns are needed.  The overarching aim of this research is to improve our understanding of the financial impact of cancer treatments, how this influences treatment decisions, and develop valid approaches to screen for financial risk within the cancer setting.

Pilot and Seed Funding Awarded:

  • CIA: Kate White
  • Member Group: University of Sydney
  • Year and Duration: 2016 for one year
  • Amount: $50,000

Select Publications/Presentations:

White K, De Abreu Lourenco R, Kenny P, Lehane L & D'Abrew N. "Dollars and Sense: Exploring the Financial Impact of Cancer for Australian Patients and their Families", Presentation, MASCC 2017 United States.

 

You might also be interested in...

  • T2,T3
    Amelia Smit: How should genomics be incorporated into Australian healthcare to improve cancer prevention and screening in the population?
    The translation of genomics has great potential to benefit cancer prevention and screening strategies in the Australian population. There is a lack of research evidence on the behavioural, psy...
      Genetics/genomics
      Clinical Trials
      Skin cancer
      Prevention and Early Detection
  • T1,T2
    Andrew Law: Understanding Molecular Mechanisms of drug Resistance At Single Cell Resolution Using Biomimetic Tissue Engineering
    Acquired drug resistance of cancer cells is one of the major challenges in having successful cancer treatment. Despite the advances of our understanding in cancer, the mechanisms and effects o...
      Treatment
  • T2,T3
    Brooke Nickel: Examination of how different terminologies for early stage cancer or precancerous conditions affect patients' psychological outcomes and decision making regarding treatment
    Changing terminology for low risk, screen detected cancers, has been recommended by several expert groups including the National Institute of Health and the National Cancer Institute in the US ...
      Psychosocial
  • T2,T3
    Cherry Koh & team: Relook Laparoscopy for Peritoneal Surface Disease (ReLaPSed) Trial
    Despite advances in surgical techniques, imaging and the availabiliy of newer chemotherapeutic agents, colorectal peritoneal metastases (PM) continues to carry a grim prognosis. Systemic ...
      Colorectal cancer
  • T2,T3
    Cindy Tan & team: Body composition changes in cancer patients during chemotherapy
    Chemotherapy dosing is generally determined by a patient's height and weight. This does not account for their body composition and can be inaccurate, particularly in people who are obese or un...
      Personalised medicine
      New therapies and diagnostics
      Colorectal cancer
  • T2,T3
    Daniel Steffens & team: Feasibility and acceptability of pre-operative exercise to improve patient outcomes after major cancer surgery: A pilot randomised controlled trial
    Promoting physical activity in the pre-operative period appears promising to improve functional capacity and facilitate post-operative recovery. This pilot study will establish the feasibility...
      Clinical Trials
      Exercise
  • T2,T3
    David Barnes and Team: Lung Cancer Demonstration Project
    Cancer Australia engaged four demonstration sites (in four States) to conduct projects that would address five principles of breast practice lung cancer care. Sydney Local Health District part...
      Implementation research
      Lung cancer
      MDT
  • T1,T2
    David Thomas: Molecular Screening and Therapeutics Program (MOST)
    The rapid advance in genomic technologies presents the unprecedented opportunity to molecularly phenotype cancers and link genetic information to therapeutic opportunities for individual patie...
      Genetics/genomics
      Personalised medicine
      New therapies and diagnostics
  • T2,T3
    Erin Moth: Understanding and optimising chemotherapy decision-making for older adults with cancer
    Geriatric oncology is an emerging subspecialty of oncology, developed in response to the ageing population. This research has broad application to clinical practice given the median age at dia...
      Psychosocial
  • T2,T3
    Jessica Lee & team: Multidisciplinary Management Of Episodic Breathlessness In Adults With Advanced Cancer - a mixed methods pilot study of a complex intervention
    This T2 project involves development and evaluation of a complex intervention to improve episodic breathlessness in adults with advanced cancer. This intervention will comprise a patient held epis...
      Clinical Trials
  • T2
    John Simes: MDT scoping project
    The aim of this research was to describe the multi-disciplinary teams (MDTs) in our consortium and to share findings with survey participants to provide them an opportunity to learn more abou...
      MDT
  • T2
    Jolyn Hersch: Supporting informed choice for management of screen-detected Ductal Carcinoma in Situ (DCIS) among older women (70 years and over)
    Breast screening often finds ductal carcinoma in situ (DCIS) - cell changes which may or may not become cancer later on. Treatments for DCIS (surgery, radiation and drugs) have harmful side ef...
      Psychosocial
      Breast Cancer
  • T1,T2
    Julius Kim & team: Systematic effects of Gioblastoma multiforme (GBM) and GBM-released extracellular vesicles on immune suppression
    Despite recent improvements in cancer therapies, the median survival for patients with brain tumours is only 15 months. We need to urgently develop better treatment options. Anti-tumour vaccin...
      Dendritic cell
  • T2,T3
    Liesbeth Geerligs: Evaluating the implementation of a clinical pathway for managing anxiety and depression in cancer patients into clinical care and policy
    Anxiety and depression are more highly prevalent in cancer patients. Evidenc ebased pathways are required to ensure that patients receive appropriate care. Effective strategies to implement su...
      Psychology
      Evidence-based practice
      Implementation research
  • T1,T2
    Megan Barnet: Genetic biomarkers for predicting response to immune checkpoint inhibitors in non-small cell lung cancer
    The 5-year survival for patients treated with anti-PD-1 in NSCLC is ~16%. We currently have no reliable tool for predicting who will benefit from this relatively tolerable single drug, and who ...
      Biomarkers
      Genetics/genomics
      Immunotherapy
      Lung cancer
  • T2,T3
    Mohsen Shafiei: Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer
    The aim of this research project is to determine and compare and pharmacokinetics (PK) of capecitabine and its metabolites in older and younger adults with cancer, and the correlation between ...
      Prospective observational study
      Drug development
      Treatment
  • T1,T2
    Natalia Pinello: RNA 5-hydroxymethylation in Haemopoiesis and Leukaemia
    My project will characterise the role of RNA modifications in normal bone marrow development and acute myeloid leukaemia, focusing on understanding how epigenetic drugs work and exploring new ...
  • T2,T3
    Nicci Bartley: Patient experience of uncertainty when undergoing cancer genomic testing
    This project will aim to understand patient experience of uncertainty when having cancer genomic testing, using questionnaires and interviews to investigate types, levels, predictors and impac...
      Genetics/genomics
      Psychosocial
      Anxiety
      Depression
  • T2,T3
    Nicola Lawrence: Optimising cooperative group cancer clinical trials in the era of molecularly targeted treatments
    The discovery and rapid development of multiple targeted therapies for malignant diseases has begun a new era of optimism in cancer drug development. These advances require a reappraisal of cl...
      Medical oncology
      Clinical Trials
  • T2
    Nicole Rankin and Team: Sydney Catalyst Member Experience Survey
    The aim of this research was to qualitatively explore the experiences of members of Sydney Catalyst to identify members' understanding and perceptions of translational research, benefits of me...
      Member Experience
  • T2,T3
    Nicole Rankin and Team: T3 Lung Cancer Flagship Program, Defining Knowledge Translation in Cancer
    The project was completed in three stages. The first stage, the team identified evidence-practice gaps in lung cancer through a scoping review and engaged clinicians from three multidiscipli...
      Intervention
      Evidence into practice
      Integrated research in quality care
      Evidence-based practice
      Implementation research
      Lung cancer
  • T2,T3
    Peey Sei Kok: What are good surrogates for clinically meaningful benefit of new oncology therapies in advanced cancers?
    Robust surrogate endpoints have the potential to reduce the clinical, economic and time burden associated with conducting RCTs and drug development. Our work will feed into future collaborative...
      Phase i/ii clinical trial
      Phase iii clinical trial
      Drug development
      Clinical Trials
  • T1,T2
    Peter Luk & team: Understanding the Body's Response to Cancer Invasion and Progression
      Cutaneous squamous cell carcinoma (cSCC; skin cancer) is the most common human cancer with the potential to spread to other parts of the body. Australia has the highest rate of cSCC i...
      Head and Neck Cancer
  • T1,T2
    Philip Hogg: Measure of thrombotic risk in cancer patients
    Thrombotic events are a major cause of death in cancer patients and are associated with worsened short‐term and long‐term survival. Prof Hogg and his team developed a new diagnostic test for ...
      Thrombosis
  • T2,T3
    Phyllis Butow & team: Anxiety and Depression Pathway Program
    Anxiety and depression are common in those diagnosed with cancer, causing suffering to individuals and their families and potentially increasing health services usage and decreasing adherence ...
      Psychosocial
      Psychology
      Evidence-based practice
      Clinical Trials
      Anxiety
      Depression
  • T2,T3
    Sara Wahlroos: The Effect of Exercise in combination with chemotherapy on breast cancer tumour biology, immunology and vascularisation - a non-pharmaceutical approach to current oncology treatment?
    In this study, Sara will examine the effect of exercise in mice with different breast cancer subtypes, to assess whether exercise has an additional effect in reducing tumour growth when combine...
      Breast Cancer
      Treatment
  • T1,T2,T3
    Sydney Catalyst Scholarships Awarded pre July 2016
    We aim to encourage training and development of outstanding researchers and clinicians from within Sydney Catalyst units, who have the potential to develop highly significant ca...
      Scholarships
  • T1,T2,T3
    Sydney Catalyst: Embedding Research in Cancer Healthcare (EnRICH)
      The EnRICH program is a prospective clinical cohort of 1000 patients with lung cancer, which aims to better define, treat and care for patients in Sydney Catalyst member hospitals...
      Epidemiology and health services research
      Implementation research
      Knowledge translation
      Lung cancer
  • T1,T2,T3
    Tahlia Scheinberg: Implications of Homologous Recombination Deficiency defects in Advanced Prostate Cancer
    Up to 12% of men with metastatic prostate cancer carry a mutation in a gene that predisposes to cancer, independent of age at diagnosis or family history of cancer. The nCCN guidelines have re...
      Prevention and Early Detection
      Urogenital
      Prostate